Seattle Genetics (SGEN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Seattle Genetics (SGEN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (16)	3/14/2002 10:24:40 PM
From: mopgcw	of 161

Seattle Genetics Licenses Monoclonal Antibodies DOW JONES NEWSWIRES BOTHELL, Wash. -- Seattle Genetics Inc. (SGEN) agreed to license certain monoclonal antibodies from Sweden's Mabtech AB. Financial terms weren't disclosed. In a press release Thursday, biotechnology company Seattle Genetics said the agreement includes multiple antibodies that target cell molecules on a variety of cancer cell types. Seattle Genetics said it has development, manufacturing and worldwide commercialization rights to therapeutic products derived from the antibodies. The company will evaluate the antibodies as therapeutic agents alone, as well as apply its antibody-drug conjugate, or ADC, technology to generate product candidates. Seattle Genetics' synthetic cytotoxic drugs and linker technology keep the ADC stable in the bloodstream, allowing for specific release of the drug inside of target cancer cells. The targeting ability of monoclonal antibodies provides a means to selectively kill cancer cells while limiting damage to normal tissue, the company said. Shares of Seattle Genetics were trading recently at $4.88, down 12 cents, or 2.4%. Company Web site: seattlegenetics.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next